My overall objective is to contribute to the understanding of why expression of specific genes is deranged in different human genetic diseases. Using restriction mapping, cloning and nucleotide suquencing, I will study the mutations, rearrangements, and altered modification states of polypeptide hormone or collagen genes that are associated with clinical symptoms. Specific objectives of these studies include determining (1) the molecular basis of growth hormone (GH) gene deletions and familial types of GH deficiency; (2) the origin of a spcific GH gene polymorphism; (3) the contributions of alterations in the parathyroid hormone (PTH) gene, its copy number or methylation state to different types of hyperparathyroidism; (4) the contribution of pro Alpha1(1) or pro Alpha2(1) collagen gene alterations to osteogenesis imperfecta (OI), OI associated with GH deficiency, or the Marfan syndrome; (5) the chromosomal assignment of the arginine vasopressin (AVP) gene, its copy number, and allelic forms seen in individuals with familial diabetes insipidus due to AVP deficiency and (6) the contribution of insulin gene alterations in certain mandelian types of diabetes mellitus. Alterations found in the polypeptide hormone or collagen genes which are associated with familial disorders affecting the expression of these genes should have similarities to defects in other inborn errors of metabolism and should provide insight into the functional relationship between normal gene structure and expression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM035592-02
Application #
3154064
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1984-08-01
Project End
1989-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Summar, M L; Phillips 3rd, J A; Battey, J et al. (1990) Linkage relationships of human arginine vasopressin-neurophysin-II and oxytocin-neurophysin-I to prodynorphin and other loci on chromosome 20. Mol Endocrinol 4:947-50
Phillips 3rd, J A; Vnencak-Jones, C L (1989) Genetics of growth hormone and its disorders. Adv Hum Genet 18:305-63
Hauffa, B P; Illig, R; Torresani, T et al. (1989) Discordant immune and growth response to pituitary and biosynthetic growth hormone in siblings with isolated growth hormone deficiency type IA. Acta Endocrinol (Copenh) 121:609-14
Summar, M L; Phillips 3rd, J A; Krishnamani, M R et al. (1989) Protein kinase C: a new linkage marker for growth hormone and for COL1A1. Genomics 5:163-5
Vnencak-Jones, C L; Phillips 3rd, J A; Chen, E Y et al. (1988) Molecular basis of human growth hormone gene deletions. Proc Natl Acad Sci U S A 85:5615-9
Phillips 3rd, J A (1988) Clinical applications of gene mapping and diagnosis. Prog Med Genet 7:68-99
Butler, M G; Repaske, D R; Joseph, G M et al. (1987) High resolution chromosome and DNA analysis in multiple endocrine neoplasia type II syndrome. Cancer Genet Cytogenet 24:129-35
Phillips 3rd, J A (1987) Gene diagnosis: detection of genetic disorders by DNA analysis. Birth Defects Orig Artic Ser 23:259-95
Matteson, K J; Phillips 3rd, J A; Miller, W L et al. (1987) P450XXI (steroid 21-hydroxylase) gene deletions are not found in family studies of congenital adrenal hyperplasia. Proc Natl Acad Sci U S A 84:5858-62
Braga, S; Phillips 3rd, J A; Joss, E et al. (1986) Familial growth hormone deficiency resulting from a 7.6 kb deletion within the growth hormone gene cluster. Am J Med Genet 25:443-52

Showing the most recent 10 out of 11 publications